Nectar Lifescience Ltd

NSE
NECLIFE •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Nectar Lifescience Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
42.4
TTM PE Ratio
High in industry
114.6
Price to Book Ratio
Low in industry
0.9
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.8
RSI
RSI is mid-range
62.6
MFI
MFI strongly Overbought
80.3

Nectar Lifescience Ltd Key Financials

*All values are in ₹ Cr.

Nectar Lifescience Ltd shareholding Pattern

Promoter
55.8%
Foreign Institutions
16.1%
Public
28%

Nectar Lifescience Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
41.50
10Day EMA
40.20
12Day EMA
39.80
20Day EMA
38.50
26Day EMA
37.70
50Day EMA
35.30
100Day EMA
31.90
200Day EMA
28.30
Delivery & Volume
Resistance & Support
41.05
Pivot
Resistance
First Resistance
42.45
Second Resistance
43.60
Third Resistance
45
Support
First Support
39.90
Second support
38.50
Third Support
37.35
Relative Strength Index
62.63
Money Flow Index
80.31
MACD
2.11
MACD Signal
1.64
Average True Range
2.67
Average Directional Index
43.83
Rate of Change (21)
22.19
Rate of Change (125)
61.96

Nectar Lifescience Ltd Company background

Founded in: 1995
Managing director: Sanjiv Goyal
Nectar Lifesciences Ltd (NLL or NECLIFE) is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 90 countries worldwide. The companys business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of APIs for pharmaceutical players.Nectar Lifesciences Ltd was incorporated on June 27, 1995 as a public limited company with the name Surya Medicare Ltd. The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation.In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs.In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001. In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a whollyowned subsidiary company in Sri Lanka to manufacture API intermediaries.In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab Industrial Policy, 2003. In the year 2004, the company started production in a portion of the new Cephalosporins plant. In March 26, 2004, the company changed their name from Surya Medicare Ltd to Nectar Lifesciences Ltd.During the year 200607, the company commissioned a stateoftheart facility dedicated to the nonantibiotic therapeutic segment in compliance with stringent USFDA and EDQM guidelines. The company established a stateoftheart mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in JK. They commissioned a unit in Derabassi to process menthol into powder and crystal formsThe company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a stateoftheart facility, Unit X at Derabassi, which commissioned on April 17, 2008.During the year 200809, the company increased the production capacity of Bulk Drug Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fullyowned formulation RD centre in Derabassi dedicated to noncephalosporins related developments like oncology, antidiabetes, cardiovascular system, female healthcare and antiHIV.During the year 200910, the company increased the production capacity of Bulk Drug Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year. During FY 201011, M/s Nectar Capital Limited was incorporated in Mauritius and M/s Nectar Lifesciences UK Limited, was incorporated in United Kingdom. Nectar Lifesciences US, LLC in United States was also incorporated during year 201415, which commenced the business operations of trading in pharmeceutical products.In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil.The company incorporated a WOS namely NECLIFE PT, UNIPESSOAL LDA in Portugal on July 11, 2019 to takeover MA from Nectar Lifesciences UK Limited. Two new innovative products in EHGC menthol capsules (Nexxicap MintyTM) and pearl capsule (Nexxicap PearlTM) were launched in 201920.
Read More

Nectar Lifescience Ltd FAQs

Nectar Lifescience Ltd shares are currently priced at 41.3 on NSE and 41.27 on BSE as of 2/21/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Nectar Lifescience Ltd [NECLIFE] share was 139.42. The Nectar Lifescience Ltd [NECLIFE] share hit a 1-year low of Rs. 14.5 and a 1-year high of Rs. 45.7.

The market cap of Nectar Lifescience Ltd is Rs. 926.2 Cr. as of 2/21/2024 12:00:00 AM.

The PE ratios of Nectar Lifescience Ltd is 93.8 as of 2/21/2024 12:00:00 AM.

The PB ratios of Nectar Lifescience Ltd is 0.86 as of 2/21/2024 12:00:00 AM

You can easily buy Nectar Lifescience Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage